Trial intelligence / Profile preview

EGLIPA: GLP-1 Agonists and Lipoprotein(a) in Type 2 Diabetes

NCT02501850Phase 4Unknown

Sponsor: Vall d'Hebron Research Institute
Start: Oct 2014
Primary completion: Jul 2015
Modality: Peptides
Countries: 1

Overview

Phase 4, open-label trial of liraglutide, exenatide and lixisenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Change in blood levels of Lipoprotein (a) at 2 months. Status: unknown.

Drugs

liraglutideexenatidelixisenatide

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on NCT02501850.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02501850.